Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эндокан – ключевой игрок при кардиоваскулярной патологии
Эндокан – ключевой игрок при кардиоваскулярной патологии
Алиева А.М., Резник Е.В., Байкова И.Е., Теплова Н.В., Макеева Л.М., Воронкова К.В., Хаджиева Н.Х., Модестова А.В., Тотолян Г.Г., Валиев Р.К., Ли А.М., Котикова И.А., Никитин И.Г. Эндокан – ключевой игрок при кардиоваскулярной патологии. Consilium Medicum. 2023;25(1):20–28.
DOI: 10.26442/20751753.2023.1.202079
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
DOI: 10.26442/20751753.2023.1.202079
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В последние годы внимание ученых активно сосредоточено на изучении роли эндокана в качестве биологического маркера эндотелиальной дисфункции при сердечно-сосудистых заболеваниях. Вплоть до последних лет эндокан изучался при остром почечном повреждении, хронической болезни почек и заместительной почечной терапии. Эндокан, ранее известный как специфическая молекула эндотелиальных клеток-1, представляет собой растворимый протеогликан дерматансульфата, экспрессируется и секретируется в кровоток из эндотелиальных клеток. Имеющиеся в настоящее время исследования демонстрируют диагностическую и прогностическую значимость оценки эндокана при сердечно-сосудистой патологии. Ожидается, что дальнейшие научно-клинические исследования продемонстрируют возможности использования эндокана в качестве дополнительного лабораторного инструмента диагностики и оценки прогноза у пациентов кардиологического профиля. Регуляция концентрации и экспрессии эндокана с помощью медикаментозных препаратов, возможно, окажется многообещающей мишенью для лечения патологии сердца и сосудов.
Ключевые слова: биологические маркеры, эндокан, атеросклероз, артериальная гипертензия, острый коронарный синдром, инфаркт миокарда, сердечная недостаточность
Keywords: biological markers, endocan, atherosclerosis, arterial hypertension, acute coronary syndrome, myocardial infarction, heart failure
Ключевые слова: биологические маркеры, эндокан, атеросклероз, артериальная гипертензия, острый коронарный синдром, инфаркт миокарда, сердечная недостаточность
________________________________________________
Keywords: biological markers, endocan, atherosclerosis, arterial hypertension, acute coronary syndrome, myocardial infarction, heart failure
Полный текст
Список литературы
1. World Health Organization. Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2019. World Health Organization. Geneva, Switzerland, 2020.
2. Копьева К.В., Гракова Е.В., Тепляков А.Т. Новые маркеры сердечной недостаточности: значение для диагностики и прогнозирования NT-proBNP и интерлейкиновых рецепторов – членов семейства ST2. Комплексные проблемы сердечно-сосудистых заболеваний. 2018;7(1):94-101 [Kopyeva KV, Grakova EV, Teplyakov AT. New markers of heart failure: implications for the diagnosis and prognosis of NT-proBNP and interleukin receptors, members of the ST2 family. Complex Problems of Cardiovascular Diseases. 2018;7(1):94-101 (in Russian)]. DOI:10.17802/2306-1278-2018-7-1-94-101
3. Алиева А.М., Резник Е.В., Гасанова Э.Т., и др. Клиническое значение определения биомаркеров крови у больных с хронической сердечной недостаточностью. Архивъ внутренней медицины. 2018;8(5):333-45 [Alieva AM, Reznik EV, Gasanova ET, et al. Clinical significance of determining blood biomarkers in patients with chronic heart failure. Archive of Internal Medicine. 2018;8(5):333-45 (in Russian)]. DOI:10.20514/2226-6704-2018-8-5-333-345
4. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. DOI:10.1093/eurheartj/ehw128
5. Алиева А.М., Алмазова И.И., Пинчук Т.В., и др. Значение копептина в диагностике и прогнозе течения сердечно-сосудистых заболеваний. Клиническая медицина. 2020;98(3):203-9 [Alieva AM, Almazova II, Pinchuk TV, et al. The value of copeptin in the diagnosis and prognosis of the course of cardiovascular diseases. Clinical Medicine. 2020;98(3):203-9 (in Russian)]. DOI:10.30629/0023-2149-2020-98-3-203-209
6. Алиева А.М., Алмазова И.И., Пинчук Т.В., и др. Фракталкин и сердечно-сосудистые заболевания. Consilium Medicum. 2020;22(5):83-6 [Alieva AM, Almazova II, Pinchuk TV, et al. Fractalkin and cardiovascular diseases. Consilium Medicum. 2020;22(5):83-6 (in Russian)]. DOI:10.26442/20751753.2020.5.200186
7. Алиева А.М., Пинчук Т.В., Алмазова И.И., и др. Клиническое значение определения биомаркера крови ST2 у больных с хронической сердечной недостаточностью. Consilium Medicum. 2021;23(6):522-6 [Alieva AM, Pinchuk TV, Almazova II, et al. Clinical significance of determination of ST2 blood biomarker in patients with chronic heart failure. Consilium Medicum. 2021;23(6):522-6 (in Russian)]. DOI:10.26442/20751753.2021.6.200606
8. Zhang J. Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. Rev Cardiovasc Med. 2022;23(2):73. DOI:10.31083/j. rcm2302073
9. Chen J, Jiang L, Yu X, et al. Endocan: A Key Player of Cardiovascular Disease. Front Cardiovasc Med. 2022;8:798699. DOI:10.3389/fcvm.2021.798699
10. Reikvam H, Hatfield K, Wendelbo O, et al. Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules. 2022;12(4):492. DOI:10.3390/biom12040492
11. Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271(34):20458-64. DOI:10.1074/jbc.271.34.20458
12. Scuruchi M, D'Ascola A, Avenoso A, et al. Endocan, a novel inflammatory marker, is upregulated in human chondrocytes stimulated with IL-1 beta. Mol Cell Biochem. 2021;476(3):1589-97. DOI:10.1007/s11010-020-04001-4
13. Lee W, Ku S, Kim S, Bae J. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229:620-30. DOI:10.1002/jcp.24485
14. Béchard D, Scherpereel A, Hammad H, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001;167:3099-106. DOI:10.4049/jimmunol.167.6.3099
15. Azimi A. Could “calprotectin” and “endocan” serve as “troponin of nephrologists”? Med Hypotheses. 2017;99:29-34. DOI:10.1016/j.mehy.2016.12.008
16. Samouilidou E, Athanasiadou V, Grapsa E. Prognostic and Diagnostic Value of Endocan in Kidney Diseases. Int J Nephrol. 2022;2022:3861092. DOI:10.1155/2022/3861092
17. Entezarian M, Ameli F, Masir N, Chin T. Significance of Endocan Expression in Various Types of Epithelial Ovarian Tumors. Iran J Pathol. 2022;17(2):202-9. DOI:10.30699/IJP.2022.540192.2740
18. Fernández-Sarmiento J, Molina C, Salazar-Pelaez L, et al. Biomarkers of Glycocalyx Injury and Endothelial Activation are Associated with Clinical Outcomes in Patients with Sepsis: A Systematic Review and Meta-Analysis. J Intensive Care Med. 2023;38(1):95-105. DOI:10.1177/08850666221109186
19. Nalewajska M, Gurazda K, Marchelek-Myśliwiec M, et al. The Role of Endocan in Selected Kidney Diseases. Int J Mol Sci. 2020;21(17):6119. DOI:10.3390/ijms21176119
20. Kumar S, Mani K. Endocan alters nitric oxide production in endothelial cells by targeting AKT/eNOS and NFkB/iNOS signaling. Nitric Oxide. 2021;117:26-33. DOI:10.1016/j.niox.2021.09.006
21. Zhao T, Kecheng Y, Zhao X, et al. The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: A meta-analysis. Medicine (Baltimore). 2018;97(49):e13407. DOI:10.1097/MD.0000000000013407
22. Musialowska D, Zbroch E, Koc-Zorawska E, et al. Endocan Concentration in Patients with Primary Hypertension. Angiology. 2018;69(6):483-9. DOI:10.1177/0003319717736158
23. Ziaee M, Mashayekhi S, Ghaffari S, et al. Predictive Value of Endocan Based on TIMI Risk Score on Major Adverse Cardiovascular Events After Acute Coronary Syndrome. Angiology. 2019;70(10):952-9. DOI:10.1177/0003319718815241
24. Kup A, Toprak C, Bayam E, et al. Serum Endocan Levels Predict Drug-Eluting Stent Restenosis in Patients with Stable Angina Pectoris. Acta Cardiol Sin. 2020;36(2):111-7. DOI:10.6515/ACS.202003_36(2).20190731A
25. Kose M, Emet S, Akpinar T, et al. Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study. Angiology. 2015;66(8):727-31. DOI:10.1177/0003319714548870
26. Lv Y, Zhang Y, Shi W, et al. The Association Between Endocan Levels and Subclinical Atherosclerosis in Patients with Type 2 Diabetes Mellitus. Am J Med Sci. 2017;353(5):433-8. DOI:10.1016/j.amjms.2017.02.004
27. Reina-Couto M, Silva-Pereira C, Pereira-Terra P, et al. Endothelitis profile in acute heart failure and cardiogenic shock patients: Endocan as a potential novel biomarker and putative therapeutic target. Front Physiol. 2022;13:965611. DOI:10.3389/fphys.2022.965611
28. Li C, Geng H, Ji L, et al. ESM-1: A Novel Tumor Biomaker and its Research Advances. Anticancer Agents Med Chem. 2019;19:1687-94. DOI:10.2174/1871520619666190705151542
29. De Freitas Caires N, Gaudet A, Portier L, et al. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care. 2018;22:280. DOI:10.1186/s13054-018-2222-7
30. Kechagia M, Papassotiriou I, Gourgoulianis KI. Endocan and the respiratory system: A review. Int J Chron Obstruct Pulmon Dis. 2016;11:3179-87. DOI:10.2147/COPD.S118692
31. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy. Biochim. Biophys. Acta Rev Cancer. 2006;1765:25-37. DOI:10.1016/j.bbcan.2005.08.004
32. De Freitas Caires N, Legendre B, Parmentier E, et al. Identification of a 14 kDa endocan fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis. J Pharm Biomed Anal. 2013;78:45-51. DOI:10.1016/j.jpba.2013.01.035
33. Gaudet A, Portier L, Mathieu D, et al. Cleaved endocan acts as a biologic competitor of endocan in the control of ICAM-1-dependent leukocyte diapedesis. J Leukoc Biol. 2020;107:833-41. DOI:10.1002/JLB.3AB0320-612RR
34. Абдурахманов З.М., Умаров Б.Я., Абдурахманов М.М. Современные биомаркеры эндотелиальной дисфункции при сердечно-сосудистых заболеваниях. Рациональная фармакотерапия в кардиологии. 2021;17(4):612-8 [Abdurakhmanov ZM, Umarov BYa, Abdurakhmanov MM. Modern biomarkers of endothelial dysfunction in cardiovascular diseases. Rational Pharmacotherapy in Cardiology. 2021;17(4):612-8 (in Russian)]. DOI:10.20996/1819-6446-2021-08-08
35. Turgunova L, Baidildina B, Laryushina Y, et al. Association of Biomarker Level with Cardiovascular Events: Results of a 4-Year Follow-Up Study. Cardiol Res Pract. 2020;2020:8020674. DOI:10.1155/2020/8020674
36. Ambrosino P, Bachetti T, D'Anna S, et al. Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension. J Cardiovasc Dev Dis. 2022;9(5):136. DOI:10.3390/jcdd9050136
37. Gallo G, Volpe M, Savoia C. Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. Front Med (Lausanne). 2022;8:798958. DOI:10.3389/fmed.2021.798958
38. Klisic A, Kavaric N, Vujcic S, et al. Endocan and advanced oxidation protein products in adult population with hypertension. Eur Rev Med Pharmacol Sci. 2020;24(12):7131-7. DOI:10.26355/eurrev_202006_21707
39. Balta S, Mikhailidis D, Demirkol S, et al. Endocan – a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65(9):773-7. DOI:10.1177/0003319713513492
40. Oktar S, Guney I, Eren S, et al. Serum endocan levels, carotid intima-media thickness and microalbuminuria in patients with newly diagnosed hypertension. Clin Exp Hypertens. 2019;41(8):787-94. DOI:10.1080/10641963.2019.1652632
41. Poon P, Ng J, Fung W, et al. Relationship between Plasma Endocan Level and Clinical Outcome of Chinese Peritoneal Dialysis Patients. Kidney Blood Press Res. 2019;44(5):1259-70. DOI:10.1159/000502961
42. Magee L, Smith G, Bloch C, et al. Guideline No. 426: Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management. J Obstet Gynaecol Can. 2022;44(5):547-71.e1. DOI:10.1016/j.jogc.2022.03.002
43. Abdull Sukor A, Ankasha S, Ugusman A, et al. Impact of offspring endothelial function from de novo hypertensive disorders during pregnancy: An evidence-based review. Front Surg. 2022;9:967785. DOI:10.3389/fsurg.2022.967785
44. Cakmak M, Yilmaz H, Bağlar E, et al. Serum levels of endocan correlate with the presence and severity of pre-eclampsia. Clin Exp Hypertens. 2016;38(2):137-42. DOI:10.3109/10641963.2015.1060993
45. Chew B, Ghazali R, Othman H, et al. Endocan expression in placenta of women with hypertension. J Obstet Gynaecol Res. 2019;45(2):345-51. DOI:10.1111/jog.13836
46. Hentschke M, da Cunha Filho E, Vieira M, et al. Negative Correlation between Placental Growth Factor and Endocan-1 in Women with Preeclampsia. Rev Bras Ginecol Obstet. 2018;40(10):593-8. DOI:10.1055/s-0038-1670713
47. Hentschke M, Lucas L, Mistry H, et al. Endocan-1 concentrations in maternal and fetal plasma and placentae in pre-eclampsia in the third trimester of pregnancy. Cytokine. 2015;74(1):152-6. DOI:10.1016/j.cyto.2015.04.013
48. Yuksel M, Tuten A, Oncul M, et al. Serum endocan concentration in women with pre-eclampsia. Arch Gynecol Obstet. 2015;292(1):69-73. DOI:10.1007/s00404-014-3605-x
49. Szpera-Goździewicz A, Kosicka K, Goździewicz T, et al. Serum endocan concentration and its correlation with severity of hypertensive disorders in pregnancy. J Matern Fetal Neonatal Med. 2020;33(14):2313-9. DOI:10.1080/14767058.2018.1548597
50. Kundi H, Gok M, Kiziltunc E, et al. The Relationship Between Serum Endocan Levels with the Presence of Slow Coronary Flow: A Cross-Sectional Study. Clin Appl Thromb Hemost. 2017;23(5):472-7. DOI:10.1177/1076029615618024
51. Ye M, Zhao Z, Luo Y, et al. Elevated endocan concentration is associated with coronary slow flow. Scand J Clin Lab Invest. 2016;76(5):345-8. DOI:10.1080/00365513.2016.1177853
52. Sığırcı S, Sarıkaya R, Keskin K, et al. Biyobelirteçler koroner yavaş akım patogenezini anlamamıza yardımcı olabilir mi? Koroner yavaş akım fenomeninde endokan ve omentin-I. Turk Kardiyol Dern Ars. 2019;47(4):251-7 [Can biomarkers help us to understand the pathogenesis of coronary slow flow? Endocan and omentin-I in slow coronary flow phenomenon. Turk Kardiyol Dern Ars. 2019;47(4):251-7 (in Turkish)]. DOI:10.5543/tkda.2018.27708
53. Ozturk S, Yetkin E, Waltenberger J. Molecular and cellular insights into the pathogenesis of coronary artery ectasia. Cardiovasc Pathol. 2018;35:37-47. DOI:10.1016/j.carpath.2018.04.005
54. Gök M, Kundi H, Kiziltunç E, et al. The relationship between serum endocan levels and the presence/severity of isolated coronary artery ectasia. Cardiovasc Endocrinol Metab. 2018;7(2):42-6. DOI:10.1097/XCE.0000000000000143
55. Turan T, Akyuz A, Aykan A, et al. Plasma Endocan Levels in Patients with Isolated Coronary Artery Ectasia. Angiology. 2016;67(10):932-6. DOI:10.1177/0003319716637789
56. Xiong C, Zhao Z, Chen Z, et al. Elevated Human Endothelial Cell-Specific Molecule-1 Level and Its Association with Coronary Artery Disease in Patients with Hypertension. J Investig Med. 2015;63(7):867-70. DOI:10.1097/JIM.0000000000000219
57. Kundi H, Balun A, Cicekcioglu H, et al. Admission Endocan Level may be a Useful Predictor for In-Hospital Mortality and Coronary Severity Index in Patients With ST-Segment Elevation Myocardial Infarction. Angiology. 2017;68(1):46-51. DOI:10.1177/0003319716646932
58. Qiu C, Fu Q, Sui J, et al. Serum Endothelial Cell-Specific Molecule 1 (Endocan) Levels in Patients with Acute Myocardial Infarction and Its Clinical Significance. Angiology. 2017;68(4):354-9. DOI:10.1177/0003319716651349
59. Efe S, Demirci K, Ozturk S, et al. Serum endocan levels in patients with cardiac syndrome X. Herz. 2018;43(4):359-63. DOI:10.1007/s00059-017-4580-3
60. Tunçez A, Altunkeser B, Ozturk B, et al. Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. Anatol J Cardiol. 2019;22(5):240-9. DOI:10.14744/AnatolJCardiol.2019.64249
61. Gok M, Kundi H, Kiziltunc E, et al. Endocan Levels and Coronary Collateral Circulation in Stable Angina Pectoris: A Pilot Study. Angiology. 2018;69(1):43-8. DOI:10.1177/0003319717703835
62. Kosir G, Jug B, Novakovic M, et al. Endocan Is an Independent Predictor of Heart Failure-Related Mortality and Hospitalizations in Patients with Chronic Stable Heart Failure. Dis Markers. 2019;2019:9134096. DOI:10.1155/2019/9134096
63. Ahmed S, Ahmed A, Bouzina H, et al. Elevated plasma endocan and BOC in heart failure patients decrease after heart transplantation in association with improved hemodynamics. Heart Vessels. 2020;35(11):1614-28. DOI:10.1007/s00380-020-01656-3
2. Kopyeva KV, Grakova EV, Teplyakov AT. New markers of heart failure: implications for the diagnosis and prognosis of NT-proBNP and interleukin receptors, members of the ST2 family. Complex Problems of Cardiovascular Diseases. 2018;7(1):94-101 (in Russian). DOI:10.17802/2306-1278-2018-7-1-94-101
3. Alieva AM, Reznik EV, Gasanova ET, et al. Clinical significance of determining blood biomarkers in patients with chronic heart failure. Archive of Internal Medicine. 2018;8(5):333-45 (in Russian). DOI:10.20514/2226-6704-2018-8-5-333-345
4. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. DOI:10.1093/eurheartj/ehw128
5. Alieva AM, Almazova II, Pinchuk TV, et al. The value of copeptin in the diagnosis and prognosis of the course of cardiovascular diseases. Clinical Medicine. 2020;98(3):203-9 (in Russian). DOI:10.30629/0023-2149-2020-98-3-203-209
6. Алиева А.М., Алмазова И.И., Пинчук Т.В., и др. Фракталкин и сердечно-сосудистые заболевания. Consilium Medicum. 2020;22(5):83-6 [Alieva AM, Almazova II, Pinchuk TV, et al. Fractalkin and cardiovascular diseases. Consilium Medicum. 2020;22(5):83-6 (in Russian)]. DOI:10.26442/20751753.2020.5.200186
7. Alieva AM, Pinchuk TV, Almazova II, et al. Clinical significance of determination of ST2 blood biomarker in patients with chronic heart failure. Consilium Medicum. 2021;23(6):522-6 (in Russian). DOI:10.26442/20751753.2021.6.200606
8. Zhang J. Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. Rev Cardiovasc Med. 2022;23(2):73. DOI:10.31083/j. rcm2302073
9. Chen J, Jiang L, Yu X, et al. Endocan: A Key Player of Cardiovascular Disease. Front Cardiovasc Med. 2022;8:798699. DOI:10.3389/fcvm.2021.798699
10. Reikvam H, Hatfield K, Wendelbo O, et al. Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules. 2022;12(4):492. DOI:10.3390/biom12040492
11. Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271(34):20458-64. DOI:10.1074/jbc.271.34.20458
12. Scuruchi M, D'Ascola A, Avenoso A, et al. Endocan, a novel inflammatory marker, is upregulated in human chondrocytes stimulated with IL-1 beta. Mol Cell Biochem. 2021;476(3):1589-97. DOI:10.1007/s11010-020-04001-4
13. Lee W, Ku S, Kim S, Bae J. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229:620-30. DOI:10.1002/jcp.24485
14. Béchard D, Scherpereel A, Hammad H, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001;167:3099-106. DOI:10.4049/jimmunol.167.6.3099
15. Azimi A. Could “calprotectin” and “endocan” serve as “troponin of nephrologists”? Med Hypotheses. 2017;99:29-34. DOI:10.1016/j.mehy.2016.12.008
16. Samouilidou E, Athanasiadou V, Grapsa E. Prognostic and Diagnostic Value of Endocan in Kidney Diseases. Int J Nephrol. 2022;2022:3861092. DOI:10.1155/2022/3861092
17. Entezarian M, Ameli F, Masir N, Chin T. Significance of Endocan Expression in Various Types of Epithelial Ovarian Tumors. Iran J Pathol. 2022;17(2):202-9. DOI:10.30699/IJP.2022.540192.2740
18. Fernández-Sarmiento J, Molina C, Salazar-Pelaez L, et al. Biomarkers of Glycocalyx Injury and Endothelial Activation are Associated with Clinical Outcomes in Patients with Sepsis: A Systematic Review and Meta-Analysis. J Intensive Care Med. 2023;38(1):95-105. DOI:10.1177/08850666221109186
19. Nalewajska M, Gurazda K, Marchelek-Myśliwiec M, et al. The Role of Endocan in Selected Kidney Diseases. Int J Mol Sci. 2020;21(17):6119. DOI:10.3390/ijms21176119
20. Kumar S, Mani K. Endocan alters nitric oxide production in endothelial cells by targeting AKT/eNOS and NFkB/iNOS signaling. Nitric Oxide. 2021;117:26-33. DOI:10.1016/j.niox.2021.09.006
21. Zhao T, Kecheng Y, Zhao X, et al. The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: A meta-analysis. Medicine (Baltimore). 2018;97(49):e13407. DOI:10.1097/MD.0000000000013407
22. Musialowska D, Zbroch E, Koc-Zorawska E, et al. Endocan Concentration in Patients with Primary Hypertension. Angiology. 2018;69(6):483-9. DOI:10.1177/0003319717736158
23. Ziaee M, Mashayekhi S, Ghaffari S, et al. Predictive Value of Endocan Based on TIMI Risk Score on Major Adverse Cardiovascular Events After Acute Coronary Syndrome. Angiology. 2019;70(10):952-9. DOI:10.1177/0003319718815241
24. Kup A, Toprak C, Bayam E, et al. Serum Endocan Levels Predict Drug-Eluting Stent Restenosis in Patients with Stable Angina Pectoris. Acta Cardiol Sin. 2020;36(2):111-7. DOI:10.6515/ACS.202003_36(2).20190731A
25. Kose M, Emet S, Akpinar T, et al. Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study. Angiology. 2015;66(8):727-31. DOI:10.1177/0003319714548870
26. Lv Y, Zhang Y, Shi W, et al. The Association Between Endocan Levels and Subclinical Atherosclerosis in Patients with Type 2 Diabetes Mellitus. Am J Med Sci. 2017;353(5):433-8. DOI:10.1016/j.amjms.2017.02.004
27. Reina-Couto M, Silva-Pereira C, Pereira-Terra P, et al. Endothelitis profile in acute heart failure and cardiogenic shock patients: Endocan as a potential novel biomarker and putative therapeutic target. Front Physiol. 2022;13:965611. DOI:10.3389/fphys.2022.965611
28. Li C, Geng H, Ji L, et al. ESM-1: A Novel Tumor Biomaker and its Research Advances. Anticancer Agents Med Chem. 2019;19:1687-94. DOI:10.2174/1871520619666190705151542
29. De Freitas Caires N, Gaudet A, Portier L, et al. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care. 2018;22:280. DOI:10.1186/s13054-018-2222-7
30. Kechagia M, Papassotiriou I, Gourgoulianis KI. Endocan and the respiratory system: A review. Int J Chron Obstruct Pulmon Dis. 2016;11:3179-87. DOI:10.2147/COPD.S118692
31. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy. Biochim. Biophys. Acta Rev Cancer. 2006;1765:25-37. DOI:10.1016/j.bbcan.2005.08.004
32. De Freitas Caires N, Legendre B, Parmentier E, et al. Identification of a 14 kDa endocan fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis. J Pharm Biomed Anal. 2013;78:45-51. DOI:10.1016/j.jpba.2013.01.035
33. Gaudet A, Portier L, Mathieu D, et al. Cleaved endocan acts as a biologic competitor of endocan in the control of ICAM-1-dependent leukocyte diapedesis. J Leukoc Biol. 2020;107:833-41. DOI:10.1002/JLB.3AB0320-612RR
34. Abdurakhmanov ZM, Umarov BYa, Abdurakhmanov MM. Modern biomarkers of endothelial dysfunction in cardiovascular diseases. Rational Pharmacotherapy in Cardiology. 2021;17(4):612-8 (in Russian). DOI:10.20996/1819-6446-2021-08-08
35. Turgunova L, Baidildina B, Laryushina Y, et al. Association of Biomarker Level with Cardiovascular Events: Results of a 4-Year Follow-Up Study. Cardiol Res Pract. 2020;2020:8020674. DOI:10.1155/2020/8020674
36. Ambrosino P, Bachetti T, D'Anna S, et al. Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension. J Cardiovasc Dev Dis. 2022;9(5):136. DOI:10.3390/jcdd9050136
37. Gallo G, Volpe M, Savoia C. Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. Front Med (Lausanne). 2022;8:798958. DOI:10.3389/fmed.2021.798958
38. Klisic A, Kavaric N, Vujcic S, et al. Endocan and advanced oxidation protein products in adult population with hypertension. Eur Rev Med Pharmacol Sci. 2020;24(12):7131-7. DOI:10.26355/eurrev_202006_21707
39. Balta S, Mikhailidis D, Demirkol S, et al. Endocan – a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65(9):773-7. DOI:10.1177/0003319713513492
40. Oktar S, Guney I, Eren S, et al. Serum endocan levels, carotid intima-media thickness and microalbuminuria in patients with newly diagnosed hypertension. Clin Exp Hypertens. 2019;41(8):787-94. DOI:10.1080/10641963.2019.1652632
41. Poon P, Ng J, Fung W, et al. Relationship between Plasma Endocan Level and Clinical Outcome of Chinese Peritoneal Dialysis Patients. Kidney Blood Press Res. 2019;44(5):1259-70. DOI:10.1159/000502961
42. Magee L, Smith G, Bloch C, et al. Guideline No. 426: Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management. J Obstet Gynaecol Can. 2022;44(5):547-71.e1. DOI:10.1016/j.jogc.2022.03.002
43. Abdull Sukor A, Ankasha S, Ugusman A, et al. Impact of offspring endothelial function from de novo hypertensive disorders during pregnancy: An evidence-based review. Front Surg. 2022;9:967785. DOI:10.3389/fsurg.2022.967785
44. Cakmak M, Yilmaz H, Bağlar E, et al. Serum levels of endocan correlate with the presence and severity of pre-eclampsia. Clin Exp Hypertens. 2016;38(2):137-42. DOI:10.3109/10641963.2015.1060993
45. Chew B, Ghazali R, Othman H, et al. Endocan expression in placenta of women with hypertension. J Obstet Gynaecol Res. 2019;45(2):345-51. DOI:10.1111/jog.13836
46. Hentschke M, da Cunha Filho E, Vieira M, et al. Negative Correlation between Placental Growth Factor and Endocan-1 in Women with Preeclampsia. Rev Bras Ginecol Obstet. 2018;40(10):593-8. DOI:10.1055/s-0038-1670713
47. Hentschke M, Lucas L, Mistry H, et al. Endocan-1 concentrations in maternal and fetal plasma and placentae in pre-eclampsia in the third trimester of pregnancy. Cytokine. 2015;74(1):152-6. DOI:10.1016/j.cyto.2015.04.013
48. Yuksel M, Tuten A, Oncul M, et al. Serum endocan concentration in women with pre-eclampsia. Arch Gynecol Obstet. 2015;292(1):69-73. DOI:10.1007/s00404-014-3605-x
49. Szpera-Goździewicz A, Kosicka K, Goździewicz T, et al. Serum endocan concentration and its correlation with severity of hypertensive disorders in pregnancy. J Matern Fetal Neonatal Med. 2020;33(14):2313-9. DOI:10.1080/14767058.2018.1548597
50. Kundi H, Gok M, Kiziltunc E, et al. The Relationship Between Serum Endocan Levels with the Presence of Slow Coronary Flow: A Cross-Sectional Study. Clin Appl Thromb Hemost. 2017;23(5):472-7. DOI:10.1177/1076029615618024
51. Ye M, Zhao Z, Luo Y, et al. Elevated endocan concentration is associated with coronary slow flow. Scand J Clin Lab Invest. 2016;76(5):345-8. DOI:10.1080/00365513.2016.1177853
52. Sığırcı S, Sarıkaya R, Keskin K, et al. Biyobelirteçler koroner yavaş akım patogenezini anlamamıza yardımcı olabilir mi? Koroner yavaş akım fenomeninde endokan ve omentin-I. Turk Kardiyol Dern Ars. 2019;47(4):251-7 [Can biomarkers help us to understand the pathogenesis of coronary slow flow? Endocan and omentin-I in slow coronary flow phenomenon. Turk Kardiyol Dern Ars. 2019;47(4):251-7 (in Turkish)]. DOI:10.5543/tkda.2018.27708
53. Ozturk S, Yetkin E, Waltenberger J. Molecular and cellular insights into the pathogenesis of coronary artery ectasia. Cardiovasc Pathol. 2018;35:37-47. DOI:10.1016/j.carpath.2018.04.005
54. Gök M, Kundi H, Kiziltunç E, et al. The relationship between serum endocan levels and the presence/severity of isolated coronary artery ectasia. Cardiovasc Endocrinol Metab. 2018;7(2):42-6. DOI:10.1097/XCE.0000000000000143
55. Turan T, Akyuz A, Aykan A, et al. Plasma Endocan Levels in Patients with Isolated Coronary Artery Ectasia. Angiology. 2016;67(10):932-6. DOI:10.1177/0003319716637789
56. Xiong C, Zhao Z, Chen Z, et al. Elevated Human Endothelial Cell-Specific Molecule-1 Level and Its Association with Coronary Artery Disease in Patients with Hypertension. J Investig Med. 2015;63(7):867-70. DOI:10.1097/JIM.0000000000000219
57. Kundi H, Balun A, Cicekcioglu H, et al. Admission Endocan Level may be a Useful Predictor for In-Hospital Mortality and Coronary Severity Index in Patients With ST-Segment Elevation Myocardial Infarction. Angiology. 2017;68(1):46-51. DOI:10.1177/0003319716646932
58. Qiu C, Fu Q, Sui J, et al. Serum Endothelial Cell-Specific Molecule 1 (Endocan) Levels in Patients with Acute Myocardial Infarction and Its Clinical Significance. Angiology. 2017;68(4):354-9. DOI:10.1177/0003319716651349
59. Efe S, Demirci K, Ozturk S, et al. Serum endocan levels in patients with cardiac syndrome X. Herz. 2018;43(4):359-63. DOI:10.1007/s00059-017-4580-3
60. Tunçez A, Altunkeser B, Ozturk B, et al. Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. Anatol J Cardiol. 2019;22(5):240-9. DOI:10.14744/AnatolJCardiol.2019.64249
61. Gok M, Kundi H, Kiziltunc E, et al. Endocan Levels and Coronary Collateral Circulation in Stable Angina Pectoris: A Pilot Study. Angiology. 2018;69(1):43-8. DOI:10.1177/0003319717703835
62. Kosir G, Jug B, Novakovic M, et al. Endocan Is an Independent Predictor of Heart Failure-Related Mortality and Hospitalizations in Patients with Chronic Stable Heart Failure. Dis Markers. 2019;2019:9134096. DOI:10.1155/2019/9134096
63. Ahmed S, Ahmed A, Bouzina H, et al. Elevated plasma endocan and BOC in heart failure patients decrease after heart transplantation in association with improved hemodynamics. Heart Vessels. 2020;35(11):1614-28. DOI:10.1007/s00380-020-01656-3
2. Копьева К.В., Гракова Е.В., Тепляков А.Т. Новые маркеры сердечной недостаточности: значение для диагностики и прогнозирования NT-proBNP и интерлейкиновых рецепторов – членов семейства ST2. Комплексные проблемы сердечно-сосудистых заболеваний. 2018;7(1):94-101 [Kopyeva KV, Grakova EV, Teplyakov AT. New markers of heart failure: implications for the diagnosis and prognosis of NT-proBNP and interleukin receptors, members of the ST2 family. Complex Problems of Cardiovascular Diseases. 2018;7(1):94-101 (in Russian)]. DOI:10.17802/2306-1278-2018-7-1-94-101
3. Алиева А.М., Резник Е.В., Гасанова Э.Т., и др. Клиническое значение определения биомаркеров крови у больных с хронической сердечной недостаточностью. Архивъ внутренней медицины. 2018;8(5):333-45 [Alieva AM, Reznik EV, Gasanova ET, et al. Clinical significance of determining blood biomarkers in patients with chronic heart failure. Archive of Internal Medicine. 2018;8(5):333-45 (in Russian)]. DOI:10.20514/2226-6704-2018-8-5-333-345
4. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. DOI:10.1093/eurheartj/ehw128
5. Алиева А.М., Алмазова И.И., Пинчук Т.В., и др. Значение копептина в диагностике и прогнозе течения сердечно-сосудистых заболеваний. Клиническая медицина. 2020;98(3):203-9 [Alieva AM, Almazova II, Pinchuk TV, et al. The value of copeptin in the diagnosis and prognosis of the course of cardiovascular diseases. Clinical Medicine. 2020;98(3):203-9 (in Russian)]. DOI:10.30629/0023-2149-2020-98-3-203-209
6. Алиева А.М., Алмазова И.И., Пинчук Т.В., и др. Фракталкин и сердечно-сосудистые заболевания. Consilium Medicum. 2020;22(5):83-6 [Alieva AM, Almazova II, Pinchuk TV, et al. Fractalkin and cardiovascular diseases. Consilium Medicum. 2020;22(5):83-6 (in Russian)]. DOI:10.26442/20751753.2020.5.200186
7. Алиева А.М., Пинчук Т.В., Алмазова И.И., и др. Клиническое значение определения биомаркера крови ST2 у больных с хронической сердечной недостаточностью. Consilium Medicum. 2021;23(6):522-6 [Alieva AM, Pinchuk TV, Almazova II, et al. Clinical significance of determination of ST2 blood biomarker in patients with chronic heart failure. Consilium Medicum. 2021;23(6):522-6 (in Russian)]. DOI:10.26442/20751753.2021.6.200606
8. Zhang J. Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. Rev Cardiovasc Med. 2022;23(2):73. DOI:10.31083/j. rcm2302073
9. Chen J, Jiang L, Yu X, et al. Endocan: A Key Player of Cardiovascular Disease. Front Cardiovasc Med. 2022;8:798699. DOI:10.3389/fcvm.2021.798699
10. Reikvam H, Hatfield K, Wendelbo O, et al. Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules. 2022;12(4):492. DOI:10.3390/biom12040492
11. Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271(34):20458-64. DOI:10.1074/jbc.271.34.20458
12. Scuruchi M, D'Ascola A, Avenoso A, et al. Endocan, a novel inflammatory marker, is upregulated in human chondrocytes stimulated with IL-1 beta. Mol Cell Biochem. 2021;476(3):1589-97. DOI:10.1007/s11010-020-04001-4
13. Lee W, Ku S, Kim S, Bae J. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229:620-30. DOI:10.1002/jcp.24485
14. Béchard D, Scherpereel A, Hammad H, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001;167:3099-106. DOI:10.4049/jimmunol.167.6.3099
15. Azimi A. Could “calprotectin” and “endocan” serve as “troponin of nephrologists”? Med Hypotheses. 2017;99:29-34. DOI:10.1016/j.mehy.2016.12.008
16. Samouilidou E, Athanasiadou V, Grapsa E. Prognostic and Diagnostic Value of Endocan in Kidney Diseases. Int J Nephrol. 2022;2022:3861092. DOI:10.1155/2022/3861092
17. Entezarian M, Ameli F, Masir N, Chin T. Significance of Endocan Expression in Various Types of Epithelial Ovarian Tumors. Iran J Pathol. 2022;17(2):202-9. DOI:10.30699/IJP.2022.540192.2740
18. Fernández-Sarmiento J, Molina C, Salazar-Pelaez L, et al. Biomarkers of Glycocalyx Injury and Endothelial Activation are Associated with Clinical Outcomes in Patients with Sepsis: A Systematic Review and Meta-Analysis. J Intensive Care Med. 2023;38(1):95-105. DOI:10.1177/08850666221109186
19. Nalewajska M, Gurazda K, Marchelek-Myśliwiec M, et al. The Role of Endocan in Selected Kidney Diseases. Int J Mol Sci. 2020;21(17):6119. DOI:10.3390/ijms21176119
20. Kumar S, Mani K. Endocan alters nitric oxide production in endothelial cells by targeting AKT/eNOS and NFkB/iNOS signaling. Nitric Oxide. 2021;117:26-33. DOI:10.1016/j.niox.2021.09.006
21. Zhao T, Kecheng Y, Zhao X, et al. The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: A meta-analysis. Medicine (Baltimore). 2018;97(49):e13407. DOI:10.1097/MD.0000000000013407
22. Musialowska D, Zbroch E, Koc-Zorawska E, et al. Endocan Concentration in Patients with Primary Hypertension. Angiology. 2018;69(6):483-9. DOI:10.1177/0003319717736158
23. Ziaee M, Mashayekhi S, Ghaffari S, et al. Predictive Value of Endocan Based on TIMI Risk Score on Major Adverse Cardiovascular Events After Acute Coronary Syndrome. Angiology. 2019;70(10):952-9. DOI:10.1177/0003319718815241
24. Kup A, Toprak C, Bayam E, et al. Serum Endocan Levels Predict Drug-Eluting Stent Restenosis in Patients with Stable Angina Pectoris. Acta Cardiol Sin. 2020;36(2):111-7. DOI:10.6515/ACS.202003_36(2).20190731A
25. Kose M, Emet S, Akpinar T, et al. Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study. Angiology. 2015;66(8):727-31. DOI:10.1177/0003319714548870
26. Lv Y, Zhang Y, Shi W, et al. The Association Between Endocan Levels and Subclinical Atherosclerosis in Patients with Type 2 Diabetes Mellitus. Am J Med Sci. 2017;353(5):433-8. DOI:10.1016/j.amjms.2017.02.004
27. Reina-Couto M, Silva-Pereira C, Pereira-Terra P, et al. Endothelitis profile in acute heart failure and cardiogenic shock patients: Endocan as a potential novel biomarker and putative therapeutic target. Front Physiol. 2022;13:965611. DOI:10.3389/fphys.2022.965611
28. Li C, Geng H, Ji L, et al. ESM-1: A Novel Tumor Biomaker and its Research Advances. Anticancer Agents Med Chem. 2019;19:1687-94. DOI:10.2174/1871520619666190705151542
29. De Freitas Caires N, Gaudet A, Portier L, et al. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care. 2018;22:280. DOI:10.1186/s13054-018-2222-7
30. Kechagia M, Papassotiriou I, Gourgoulianis KI. Endocan and the respiratory system: A review. Int J Chron Obstruct Pulmon Dis. 2016;11:3179-87. DOI:10.2147/COPD.S118692
31. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy. Biochim. Biophys. Acta Rev Cancer. 2006;1765:25-37. DOI:10.1016/j.bbcan.2005.08.004
32. De Freitas Caires N, Legendre B, Parmentier E, et al. Identification of a 14 kDa endocan fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis. J Pharm Biomed Anal. 2013;78:45-51. DOI:10.1016/j.jpba.2013.01.035
33. Gaudet A, Portier L, Mathieu D, et al. Cleaved endocan acts as a biologic competitor of endocan in the control of ICAM-1-dependent leukocyte diapedesis. J Leukoc Biol. 2020;107:833-41. DOI:10.1002/JLB.3AB0320-612RR
34. Абдурахманов З.М., Умаров Б.Я., Абдурахманов М.М. Современные биомаркеры эндотелиальной дисфункции при сердечно-сосудистых заболеваниях. Рациональная фармакотерапия в кардиологии. 2021;17(4):612-8 [Abdurakhmanov ZM, Umarov BYa, Abdurakhmanov MM. Modern biomarkers of endothelial dysfunction in cardiovascular diseases. Rational Pharmacotherapy in Cardiology. 2021;17(4):612-8 (in Russian)]. DOI:10.20996/1819-6446-2021-08-08
35. Turgunova L, Baidildina B, Laryushina Y, et al. Association of Biomarker Level with Cardiovascular Events: Results of a 4-Year Follow-Up Study. Cardiol Res Pract. 2020;2020:8020674. DOI:10.1155/2020/8020674
36. Ambrosino P, Bachetti T, D'Anna S, et al. Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension. J Cardiovasc Dev Dis. 2022;9(5):136. DOI:10.3390/jcdd9050136
37. Gallo G, Volpe M, Savoia C. Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. Front Med (Lausanne). 2022;8:798958. DOI:10.3389/fmed.2021.798958
38. Klisic A, Kavaric N, Vujcic S, et al. Endocan and advanced oxidation protein products in adult population with hypertension. Eur Rev Med Pharmacol Sci. 2020;24(12):7131-7. DOI:10.26355/eurrev_202006_21707
39. Balta S, Mikhailidis D, Demirkol S, et al. Endocan – a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65(9):773-7. DOI:10.1177/0003319713513492
40. Oktar S, Guney I, Eren S, et al. Serum endocan levels, carotid intima-media thickness and microalbuminuria in patients with newly diagnosed hypertension. Clin Exp Hypertens. 2019;41(8):787-94. DOI:10.1080/10641963.2019.1652632
41. Poon P, Ng J, Fung W, et al. Relationship between Plasma Endocan Level and Clinical Outcome of Chinese Peritoneal Dialysis Patients. Kidney Blood Press Res. 2019;44(5):1259-70. DOI:10.1159/000502961
42. Magee L, Smith G, Bloch C, et al. Guideline No. 426: Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management. J Obstet Gynaecol Can. 2022;44(5):547-71.e1. DOI:10.1016/j.jogc.2022.03.002
43. Abdull Sukor A, Ankasha S, Ugusman A, et al. Impact of offspring endothelial function from de novo hypertensive disorders during pregnancy: An evidence-based review. Front Surg. 2022;9:967785. DOI:10.3389/fsurg.2022.967785
44. Cakmak M, Yilmaz H, Bağlar E, et al. Serum levels of endocan correlate with the presence and severity of pre-eclampsia. Clin Exp Hypertens. 2016;38(2):137-42. DOI:10.3109/10641963.2015.1060993
45. Chew B, Ghazali R, Othman H, et al. Endocan expression in placenta of women with hypertension. J Obstet Gynaecol Res. 2019;45(2):345-51. DOI:10.1111/jog.13836
46. Hentschke M, da Cunha Filho E, Vieira M, et al. Negative Correlation between Placental Growth Factor and Endocan-1 in Women with Preeclampsia. Rev Bras Ginecol Obstet. 2018;40(10):593-8. DOI:10.1055/s-0038-1670713
47. Hentschke M, Lucas L, Mistry H, et al. Endocan-1 concentrations in maternal and fetal plasma and placentae in pre-eclampsia in the third trimester of pregnancy. Cytokine. 2015;74(1):152-6. DOI:10.1016/j.cyto.2015.04.013
48. Yuksel M, Tuten A, Oncul M, et al. Serum endocan concentration in women with pre-eclampsia. Arch Gynecol Obstet. 2015;292(1):69-73. DOI:10.1007/s00404-014-3605-x
49. Szpera-Goździewicz A, Kosicka K, Goździewicz T, et al. Serum endocan concentration and its correlation with severity of hypertensive disorders in pregnancy. J Matern Fetal Neonatal Med. 2020;33(14):2313-9. DOI:10.1080/14767058.2018.1548597
50. Kundi H, Gok M, Kiziltunc E, et al. The Relationship Between Serum Endocan Levels with the Presence of Slow Coronary Flow: A Cross-Sectional Study. Clin Appl Thromb Hemost. 2017;23(5):472-7. DOI:10.1177/1076029615618024
51. Ye M, Zhao Z, Luo Y, et al. Elevated endocan concentration is associated with coronary slow flow. Scand J Clin Lab Invest. 2016;76(5):345-8. DOI:10.1080/00365513.2016.1177853
52. Sığırcı S, Sarıkaya R, Keskin K, et al. Biyobelirteçler koroner yavaş akım patogenezini anlamamıza yardımcı olabilir mi? Koroner yavaş akım fenomeninde endokan ve omentin-I. Turk Kardiyol Dern Ars. 2019;47(4):251-7 [Can biomarkers help us to understand the pathogenesis of coronary slow flow? Endocan and omentin-I in slow coronary flow phenomenon. Turk Kardiyol Dern Ars. 2019;47(4):251-7 (in Turkish)]. DOI:10.5543/tkda.2018.27708
53. Ozturk S, Yetkin E, Waltenberger J. Molecular and cellular insights into the pathogenesis of coronary artery ectasia. Cardiovasc Pathol. 2018;35:37-47. DOI:10.1016/j.carpath.2018.04.005
54. Gök M, Kundi H, Kiziltunç E, et al. The relationship between serum endocan levels and the presence/severity of isolated coronary artery ectasia. Cardiovasc Endocrinol Metab. 2018;7(2):42-6. DOI:10.1097/XCE.0000000000000143
55. Turan T, Akyuz A, Aykan A, et al. Plasma Endocan Levels in Patients with Isolated Coronary Artery Ectasia. Angiology. 2016;67(10):932-6. DOI:10.1177/0003319716637789
56. Xiong C, Zhao Z, Chen Z, et al. Elevated Human Endothelial Cell-Specific Molecule-1 Level and Its Association with Coronary Artery Disease in Patients with Hypertension. J Investig Med. 2015;63(7):867-70. DOI:10.1097/JIM.0000000000000219
57. Kundi H, Balun A, Cicekcioglu H, et al. Admission Endocan Level may be a Useful Predictor for In-Hospital Mortality and Coronary Severity Index in Patients With ST-Segment Elevation Myocardial Infarction. Angiology. 2017;68(1):46-51. DOI:10.1177/0003319716646932
58. Qiu C, Fu Q, Sui J, et al. Serum Endothelial Cell-Specific Molecule 1 (Endocan) Levels in Patients with Acute Myocardial Infarction and Its Clinical Significance. Angiology. 2017;68(4):354-9. DOI:10.1177/0003319716651349
59. Efe S, Demirci K, Ozturk S, et al. Serum endocan levels in patients with cardiac syndrome X. Herz. 2018;43(4):359-63. DOI:10.1007/s00059-017-4580-3
60. Tunçez A, Altunkeser B, Ozturk B, et al. Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. Anatol J Cardiol. 2019;22(5):240-9. DOI:10.14744/AnatolJCardiol.2019.64249
61. Gok M, Kundi H, Kiziltunc E, et al. Endocan Levels and Coronary Collateral Circulation in Stable Angina Pectoris: A Pilot Study. Angiology. 2018;69(1):43-8. DOI:10.1177/0003319717703835
62. Kosir G, Jug B, Novakovic M, et al. Endocan Is an Independent Predictor of Heart Failure-Related Mortality and Hospitalizations in Patients with Chronic Stable Heart Failure. Dis Markers. 2019;2019:9134096. DOI:10.1155/2019/9134096
63. Ahmed S, Ahmed A, Bouzina H, et al. Elevated plasma endocan and BOC in heart failure patients decrease after heart transplantation in association with improved hemodynamics. Heart Vessels. 2020;35(11):1614-28. DOI:10.1007/s00380-020-01656-3
________________________________________________
2. Kopyeva KV, Grakova EV, Teplyakov AT. New markers of heart failure: implications for the diagnosis and prognosis of NT-proBNP and interleukin receptors, members of the ST2 family. Complex Problems of Cardiovascular Diseases. 2018;7(1):94-101 (in Russian). DOI:10.17802/2306-1278-2018-7-1-94-101
3. Alieva AM, Reznik EV, Gasanova ET, et al. Clinical significance of determining blood biomarkers in patients with chronic heart failure. Archive of Internal Medicine. 2018;8(5):333-45 (in Russian). DOI:10.20514/2226-6704-2018-8-5-333-345
4. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. DOI:10.1093/eurheartj/ehw128
5. Alieva AM, Almazova II, Pinchuk TV, et al. The value of copeptin in the diagnosis and prognosis of the course of cardiovascular diseases. Clinical Medicine. 2020;98(3):203-9 (in Russian). DOI:10.30629/0023-2149-2020-98-3-203-209
6. Алиева А.М., Алмазова И.И., Пинчук Т.В., и др. Фракталкин и сердечно-сосудистые заболевания. Consilium Medicum. 2020;22(5):83-6 [Alieva AM, Almazova II, Pinchuk TV, et al. Fractalkin and cardiovascular diseases. Consilium Medicum. 2020;22(5):83-6 (in Russian)]. DOI:10.26442/20751753.2020.5.200186
7. Alieva AM, Pinchuk TV, Almazova II, et al. Clinical significance of determination of ST2 blood biomarker in patients with chronic heart failure. Consilium Medicum. 2021;23(6):522-6 (in Russian). DOI:10.26442/20751753.2021.6.200606
8. Zhang J. Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. Rev Cardiovasc Med. 2022;23(2):73. DOI:10.31083/j. rcm2302073
9. Chen J, Jiang L, Yu X, et al. Endocan: A Key Player of Cardiovascular Disease. Front Cardiovasc Med. 2022;8:798699. DOI:10.3389/fcvm.2021.798699
10. Reikvam H, Hatfield K, Wendelbo O, et al. Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules. 2022;12(4):492. DOI:10.3390/biom12040492
11. Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271(34):20458-64. DOI:10.1074/jbc.271.34.20458
12. Scuruchi M, D'Ascola A, Avenoso A, et al. Endocan, a novel inflammatory marker, is upregulated in human chondrocytes stimulated with IL-1 beta. Mol Cell Biochem. 2021;476(3):1589-97. DOI:10.1007/s11010-020-04001-4
13. Lee W, Ku S, Kim S, Bae J. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229:620-30. DOI:10.1002/jcp.24485
14. Béchard D, Scherpereel A, Hammad H, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001;167:3099-106. DOI:10.4049/jimmunol.167.6.3099
15. Azimi A. Could “calprotectin” and “endocan” serve as “troponin of nephrologists”? Med Hypotheses. 2017;99:29-34. DOI:10.1016/j.mehy.2016.12.008
16. Samouilidou E, Athanasiadou V, Grapsa E. Prognostic and Diagnostic Value of Endocan in Kidney Diseases. Int J Nephrol. 2022;2022:3861092. DOI:10.1155/2022/3861092
17. Entezarian M, Ameli F, Masir N, Chin T. Significance of Endocan Expression in Various Types of Epithelial Ovarian Tumors. Iran J Pathol. 2022;17(2):202-9. DOI:10.30699/IJP.2022.540192.2740
18. Fernández-Sarmiento J, Molina C, Salazar-Pelaez L, et al. Biomarkers of Glycocalyx Injury and Endothelial Activation are Associated with Clinical Outcomes in Patients with Sepsis: A Systematic Review and Meta-Analysis. J Intensive Care Med. 2023;38(1):95-105. DOI:10.1177/08850666221109186
19. Nalewajska M, Gurazda K, Marchelek-Myśliwiec M, et al. The Role of Endocan in Selected Kidney Diseases. Int J Mol Sci. 2020;21(17):6119. DOI:10.3390/ijms21176119
20. Kumar S, Mani K. Endocan alters nitric oxide production in endothelial cells by targeting AKT/eNOS and NFkB/iNOS signaling. Nitric Oxide. 2021;117:26-33. DOI:10.1016/j.niox.2021.09.006
21. Zhao T, Kecheng Y, Zhao X, et al. The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: A meta-analysis. Medicine (Baltimore). 2018;97(49):e13407. DOI:10.1097/MD.0000000000013407
22. Musialowska D, Zbroch E, Koc-Zorawska E, et al. Endocan Concentration in Patients with Primary Hypertension. Angiology. 2018;69(6):483-9. DOI:10.1177/0003319717736158
23. Ziaee M, Mashayekhi S, Ghaffari S, et al. Predictive Value of Endocan Based on TIMI Risk Score on Major Adverse Cardiovascular Events After Acute Coronary Syndrome. Angiology. 2019;70(10):952-9. DOI:10.1177/0003319718815241
24. Kup A, Toprak C, Bayam E, et al. Serum Endocan Levels Predict Drug-Eluting Stent Restenosis in Patients with Stable Angina Pectoris. Acta Cardiol Sin. 2020;36(2):111-7. DOI:10.6515/ACS.202003_36(2).20190731A
25. Kose M, Emet S, Akpinar T, et al. Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study. Angiology. 2015;66(8):727-31. DOI:10.1177/0003319714548870
26. Lv Y, Zhang Y, Shi W, et al. The Association Between Endocan Levels and Subclinical Atherosclerosis in Patients with Type 2 Diabetes Mellitus. Am J Med Sci. 2017;353(5):433-8. DOI:10.1016/j.amjms.2017.02.004
27. Reina-Couto M, Silva-Pereira C, Pereira-Terra P, et al. Endothelitis profile in acute heart failure and cardiogenic shock patients: Endocan as a potential novel biomarker and putative therapeutic target. Front Physiol. 2022;13:965611. DOI:10.3389/fphys.2022.965611
28. Li C, Geng H, Ji L, et al. ESM-1: A Novel Tumor Biomaker and its Research Advances. Anticancer Agents Med Chem. 2019;19:1687-94. DOI:10.2174/1871520619666190705151542
29. De Freitas Caires N, Gaudet A, Portier L, et al. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care. 2018;22:280. DOI:10.1186/s13054-018-2222-7
30. Kechagia M, Papassotiriou I, Gourgoulianis KI. Endocan and the respiratory system: A review. Int J Chron Obstruct Pulmon Dis. 2016;11:3179-87. DOI:10.2147/COPD.S118692
31. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy. Biochim. Biophys. Acta Rev Cancer. 2006;1765:25-37. DOI:10.1016/j.bbcan.2005.08.004
32. De Freitas Caires N, Legendre B, Parmentier E, et al. Identification of a 14 kDa endocan fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis. J Pharm Biomed Anal. 2013;78:45-51. DOI:10.1016/j.jpba.2013.01.035
33. Gaudet A, Portier L, Mathieu D, et al. Cleaved endocan acts as a biologic competitor of endocan in the control of ICAM-1-dependent leukocyte diapedesis. J Leukoc Biol. 2020;107:833-41. DOI:10.1002/JLB.3AB0320-612RR
34. Abdurakhmanov ZM, Umarov BYa, Abdurakhmanov MM. Modern biomarkers of endothelial dysfunction in cardiovascular diseases. Rational Pharmacotherapy in Cardiology. 2021;17(4):612-8 (in Russian). DOI:10.20996/1819-6446-2021-08-08
35. Turgunova L, Baidildina B, Laryushina Y, et al. Association of Biomarker Level with Cardiovascular Events: Results of a 4-Year Follow-Up Study. Cardiol Res Pract. 2020;2020:8020674. DOI:10.1155/2020/8020674
36. Ambrosino P, Bachetti T, D'Anna S, et al. Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension. J Cardiovasc Dev Dis. 2022;9(5):136. DOI:10.3390/jcdd9050136
37. Gallo G, Volpe M, Savoia C. Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. Front Med (Lausanne). 2022;8:798958. DOI:10.3389/fmed.2021.798958
38. Klisic A, Kavaric N, Vujcic S, et al. Endocan and advanced oxidation protein products in adult population with hypertension. Eur Rev Med Pharmacol Sci. 2020;24(12):7131-7. DOI:10.26355/eurrev_202006_21707
39. Balta S, Mikhailidis D, Demirkol S, et al. Endocan – a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65(9):773-7. DOI:10.1177/0003319713513492
40. Oktar S, Guney I, Eren S, et al. Serum endocan levels, carotid intima-media thickness and microalbuminuria in patients with newly diagnosed hypertension. Clin Exp Hypertens. 2019;41(8):787-94. DOI:10.1080/10641963.2019.1652632
41. Poon P, Ng J, Fung W, et al. Relationship between Plasma Endocan Level and Clinical Outcome of Chinese Peritoneal Dialysis Patients. Kidney Blood Press Res. 2019;44(5):1259-70. DOI:10.1159/000502961
42. Magee L, Smith G, Bloch C, et al. Guideline No. 426: Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management. J Obstet Gynaecol Can. 2022;44(5):547-71.e1. DOI:10.1016/j.jogc.2022.03.002
43. Abdull Sukor A, Ankasha S, Ugusman A, et al. Impact of offspring endothelial function from de novo hypertensive disorders during pregnancy: An evidence-based review. Front Surg. 2022;9:967785. DOI:10.3389/fsurg.2022.967785
44. Cakmak M, Yilmaz H, Bağlar E, et al. Serum levels of endocan correlate with the presence and severity of pre-eclampsia. Clin Exp Hypertens. 2016;38(2):137-42. DOI:10.3109/10641963.2015.1060993
45. Chew B, Ghazali R, Othman H, et al. Endocan expression in placenta of women with hypertension. J Obstet Gynaecol Res. 2019;45(2):345-51. DOI:10.1111/jog.13836
46. Hentschke M, da Cunha Filho E, Vieira M, et al. Negative Correlation between Placental Growth Factor and Endocan-1 in Women with Preeclampsia. Rev Bras Ginecol Obstet. 2018;40(10):593-8. DOI:10.1055/s-0038-1670713
47. Hentschke M, Lucas L, Mistry H, et al. Endocan-1 concentrations in maternal and fetal plasma and placentae in pre-eclampsia in the third trimester of pregnancy. Cytokine. 2015;74(1):152-6. DOI:10.1016/j.cyto.2015.04.013
48. Yuksel M, Tuten A, Oncul M, et al. Serum endocan concentration in women with pre-eclampsia. Arch Gynecol Obstet. 2015;292(1):69-73. DOI:10.1007/s00404-014-3605-x
49. Szpera-Goździewicz A, Kosicka K, Goździewicz T, et al. Serum endocan concentration and its correlation with severity of hypertensive disorders in pregnancy. J Matern Fetal Neonatal Med. 2020;33(14):2313-9. DOI:10.1080/14767058.2018.1548597
50. Kundi H, Gok M, Kiziltunc E, et al. The Relationship Between Serum Endocan Levels with the Presence of Slow Coronary Flow: A Cross-Sectional Study. Clin Appl Thromb Hemost. 2017;23(5):472-7. DOI:10.1177/1076029615618024
51. Ye M, Zhao Z, Luo Y, et al. Elevated endocan concentration is associated with coronary slow flow. Scand J Clin Lab Invest. 2016;76(5):345-8. DOI:10.1080/00365513.2016.1177853
52. Sığırcı S, Sarıkaya R, Keskin K, et al. Biyobelirteçler koroner yavaş akım patogenezini anlamamıza yardımcı olabilir mi? Koroner yavaş akım fenomeninde endokan ve omentin-I. Turk Kardiyol Dern Ars. 2019;47(4):251-7 [Can biomarkers help us to understand the pathogenesis of coronary slow flow? Endocan and omentin-I in slow coronary flow phenomenon. Turk Kardiyol Dern Ars. 2019;47(4):251-7 (in Turkish)]. DOI:10.5543/tkda.2018.27708
53. Ozturk S, Yetkin E, Waltenberger J. Molecular and cellular insights into the pathogenesis of coronary artery ectasia. Cardiovasc Pathol. 2018;35:37-47. DOI:10.1016/j.carpath.2018.04.005
54. Gök M, Kundi H, Kiziltunç E, et al. The relationship between serum endocan levels and the presence/severity of isolated coronary artery ectasia. Cardiovasc Endocrinol Metab. 2018;7(2):42-6. DOI:10.1097/XCE.0000000000000143
55. Turan T, Akyuz A, Aykan A, et al. Plasma Endocan Levels in Patients with Isolated Coronary Artery Ectasia. Angiology. 2016;67(10):932-6. DOI:10.1177/0003319716637789
56. Xiong C, Zhao Z, Chen Z, et al. Elevated Human Endothelial Cell-Specific Molecule-1 Level and Its Association with Coronary Artery Disease in Patients with Hypertension. J Investig Med. 2015;63(7):867-70. DOI:10.1097/JIM.0000000000000219
57. Kundi H, Balun A, Cicekcioglu H, et al. Admission Endocan Level may be a Useful Predictor for In-Hospital Mortality and Coronary Severity Index in Patients With ST-Segment Elevation Myocardial Infarction. Angiology. 2017;68(1):46-51. DOI:10.1177/0003319716646932
58. Qiu C, Fu Q, Sui J, et al. Serum Endothelial Cell-Specific Molecule 1 (Endocan) Levels in Patients with Acute Myocardial Infarction and Its Clinical Significance. Angiology. 2017;68(4):354-9. DOI:10.1177/0003319716651349
59. Efe S, Demirci K, Ozturk S, et al. Serum endocan levels in patients with cardiac syndrome X. Herz. 2018;43(4):359-63. DOI:10.1007/s00059-017-4580-3
60. Tunçez A, Altunkeser B, Ozturk B, et al. Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction. Anatol J Cardiol. 2019;22(5):240-9. DOI:10.14744/AnatolJCardiol.2019.64249
61. Gok M, Kundi H, Kiziltunc E, et al. Endocan Levels and Coronary Collateral Circulation in Stable Angina Pectoris: A Pilot Study. Angiology. 2018;69(1):43-8. DOI:10.1177/0003319717703835
62. Kosir G, Jug B, Novakovic M, et al. Endocan Is an Independent Predictor of Heart Failure-Related Mortality and Hospitalizations in Patients with Chronic Stable Heart Failure. Dis Markers. 2019;2019:9134096. DOI:10.1155/2019/9134096
63. Ahmed S, Ahmed A, Bouzina H, et al. Elevated plasma endocan and BOC in heart failure patients decrease after heart transplantation in association with improved hemodynamics. Heart Vessels. 2020;35(11):1614-28. DOI:10.1007/s00380-020-01656-3
Авторы
А.М. Алиева*1, Е.В. Резник1, И.Е. Байкова1, Н.В. Теплова1, Л.М. Макеева1, К.В. Воронкова1, Н.Х. Хаджиева2, А.В. Модестова1, Г.Г. Тотолян1, Р.К. Валиев3, А.М. Ли4, И.А. Котикова1, И.Г. Никитин1
1 ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
2 ЧУЗ «Центральная клиническая больница “РЖД-Медицина”», Москва, Россия;
3 ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы, Москва, Россия;
4 АО «Группа компаний “МЕДСИ”», Москва, Россия
*amisha_alieva@mail.ru
1 Pirogov Russian National Research Medical University, Moscow, Russia;
2 Central Clinical Hospital “RZD-Medicine”, Moscow, Russia;
3 Loginov Moscow Clinical Scientific Center, Moscow, Russia;
4 MEDSI Group of Companies, Moscow, Russia
*amisha_alieva@mail.ru
1 ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
2 ЧУЗ «Центральная клиническая больница “РЖД-Медицина”», Москва, Россия;
3 ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы, Москва, Россия;
4 АО «Группа компаний “МЕДСИ”», Москва, Россия
*amisha_alieva@mail.ru
________________________________________________
1 Pirogov Russian National Research Medical University, Moscow, Russia;
2 Central Clinical Hospital “RZD-Medicine”, Moscow, Russia;
3 Loginov Moscow Clinical Scientific Center, Moscow, Russia;
4 MEDSI Group of Companies, Moscow, Russia
*amisha_alieva@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.